ALK Fusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy

BACKGROUND. Genomic fusions of the anaplastic lymphoma kinase gene (ALK) are a well‐established therapy target in non‐small cell lung cancer (NSCLC). From a survey of 114,200 clinical cases, we determined the prevalence of ALK rearrangements (rALK) in non‐NSCLC tumors and report their responsiveness...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncologist
Κύριοι συγγραφείς: Ross, Jeffrey S., Ali, Siraj M., Fasan, Omotayo, Block, Jared, Pal, Sumanta, Elvin, Julia A., Schrock, Alexa B., Suh, James, Nozad, Sahar, Kim, Sungeun, Jeong Lee, Hwa, Sheehan, Christine E., Jones, David M., Vergilio, Jo‐Anne, Ramkissoon, Shakti, Severson, Eric, Daniel, Sugganth, Fabrizio, David, Frampton, Garrett, Miller, Vince A., Stephens, Philip J., Gay, Laurie M.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: AlphaMed Press 2017
Θέματα:
Cancer Diagnostics and Molecular Pathology
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728036/
https://ncbi.nlm.nih.gov/pubmed/29079636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0488
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια